Cellectar BiosciencesCLRB
13F holders, Q2 2026 (June 30)29holders +10
13new positions
4sold out
$2.79avg. 13F price*
At the end of Q2 2026, 29 institutions reported holding Cellectar Biosciences Inc. (CLRB) in their 13F filings, up 10 from Q1 2026. 13 opened new positions and 4 sold out. The largest holders were Caligan Partners LP ($1.3M), Stempoint Capital LP ($987K) and Vanguard Capital Management LLC ($910K).
- Company
- Cellectar Biosciences Inc.
- CUSIP
- 15117F880
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 13 | $6.2M |
| Exits | 4 | $39K |
All 13F filers, Q1 2026 → Q2 2026: 2,696,575 shares bought and 21,830 shares sold, net +2,674,745 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 29 holders
| Caligan Partners LP | 0.06% | New | 469,998 | $1.3M |
| Stempoint Capital LP | 0.17% | New | 354,938 | $987K |
| Vanguard Capital Management LLC | 0.00% | Add +299.8% | 327,367 | $910K |
| Silverarc Capital Management, LLC | 0.10% | New | 321,728 | $894K |
| Bleichroeder LP | 0.14% | Add +188.7% | 288,679 | $803K |
| Jupiter Topco LLC | 0.00% | — | 274,156 | $759K |
| Balyasny Asset Management L.P. | 0.00% | New | 220,000 | $612K |
| Nantahala Capital Management, LLC | 0.04% | New | 219,998 | $612K |
| Empery Asset Management, LP | 0.62% | New | 189,605 | $527K |
| Diadema Partners LP | 0.15% | New | 138,341 | $385K |
| Stonepine Capital Management, LLC | 0.22% | New | 104,550 | $291K |
| Persistent Asset Partners Ltd | 0.08% | New | 92,983 | $258K |
| Boothbay Fund Management, LLC | 0.00% | New | 85,069 | $236K |
| Geode Capital Management, LLC | 0.00% | Add +1.1% | 53,351 | $148K |
| Vanguard Fiduciary Trust Co. | 0.00% | Add +178.9% | 46,220 | $128K |
| Sequoia Financial Advisors, LLC | 0.00% | Add +15.9% | 21,850 | $61K |
| Riverview Capital Advisers, LLC | 0.01% | No change | 10,384 | $50K |
| Acadian Asset Management LLC | 0.00% | New | 16,577 | $46K |
| Northern Trust Corp. | 0.00% | New | 14,839 | $41K |
| BlackRock, Inc. | 0.00% | Reduce -0.2% | 4,735 | $13K |
| UBS Group AG | 0.00% | Reduce -67.9% | 3,093 | $9K |
| Barclays PLC | 0.00% | New | 561 | $2K |
| Morgan Stanley | 0.00% | No change | 510 | $1K |
| TD Waterhouse Canada Inc. | 0.00% | No change | 63 | $178 |
| SBI Securities Co., Ltd. | 0.00% | No change | 11 | $31 |
| Osaic Holdings, Inc. | 0.00% | Add +600.0% | 7 | $18 |
| US Bancorp \de | 0.00% | No change | 3 | $8 |
| Jones Financial Companies LLLP | 0.00% | No change | 3 | $8 |
| Danske Bank A/S | 0.00% | No change | 2 | $6 |
"% of holder's portfolio" is CLRB's weight in each manager's 13F, not the share of Cellectar Biosciences Inc. the manager owns.